Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aikeqing** is an orally administered multi-herb traditional Chinese medicine preparation formulated as a capsule and investigated as an adjunct to highly active antiretroviral therapy for HIV infection and acquired immune deficiency syndrome. Its composition includes botanical constituents standardized analytically using icariin, polydatin, glycyrrhizic acid, and baicalin as marker compounds. No single direct molecular target or validated target-level mechanism has been established. In clinical studies it was evaluated for reducing HAART-associated toxicity and resistance-related concerns, while a SHIV89.6-infected Chinese rhesus macaque study reported reduced plasma viral load with early high-dose treatment. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=5855))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aikeqing.